Get the Stockscreener App
185.10
0.05%
0.5708
Glaukos Corp stock is traded at $185.10, with a volume of 340.55K.
It is up +0.05% in the last 24 hours and up +17.72% over the past month.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
See More
Previous Close:
$184.53
Open:
$183.55
24h Volume:
340.55K
Relative Volume:
0.34
Market Cap:
$10.92B
Revenue:
$551.35M
Net Income/Loss:
$-189.33M
P/E Ratio:
-56.23
EPS:
-3.2916
Net Cash Flow:
$-35.09M
1W Performance:
+1.77%
1M Performance:
+17.72%
6M Performance:
+73.13%
1Y Performance:
+105.46%
1-Day Range:
$181.84
$186.03
1-Week Range:
$177.56
$190.00
52-Week Range:
$73.16
$190.00
Glaukos Corp Stock (GKOS) Company Profile
Name
Glaukos Corp
Sector
Industry
Phone
949-367-9600
Address
1 GLAUKOS WAY, ALISO VIEJO, CA
Compare GKOS vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GKOS
Glaukos Corp
|
185.10 | 10.88B | 551.35M | -189.33M | -35.09M | -3.2916 |
ABT
Abbott Laboratories
|
110.12 | 192.51B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
332.32 | 130.11B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
90.64 | 116.83B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
51.55 | 75.11B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
90.80 | 52.80B | 6.30B | 1.07B | 1.09B | 1.8406 |
Glaukos Corp Stock (GKOS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-06-26 | Initiated | H.C. Wainwright | Buy |
| Oct-27-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-01-25 | Initiated | Goldman | Buy |
| May-01-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-19-25 | Upgrade | Mizuho | Neutral → Outperform |
| Dec-11-24 | Upgrade | Citigroup | Neutral → Buy |
| Dec-06-24 | Initiated | UBS | Buy |
| Dec-02-24 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-10-24 | Downgrade | Citigroup | Buy → Neutral |
| May-06-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-21-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-04-23 | Initiated | Morgan Stanley | Equal-Weight |
| Nov-28-23 | Initiated | Truist | Buy |
| Nov-08-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jun-07-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-22-22 | Initiated | Mizuho | Neutral |
| Dec-19-22 | Upgrade | JP Morgan | Underweight → Neutral |
| Dec-12-22 | Upgrade | Citigroup | Neutral → Buy |
| Oct-14-22 | Resumed | Stephens | Overweight |
| Oct-04-22 | Initiated | Needham | Buy |
| Jul-12-22 | Upgrade | Stifel | Hold → Buy |
| Feb-03-22 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-19-22 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Jan-18-22 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-03-21 | Upgrade | Stephens | Equal-Weight → Overweight |
| Jul-26-21 | Downgrade | Stephens | Overweight → Equal-Weight |
| Jul-20-21 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| Jul-14-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-14-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Apr-08-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-29-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-16-20 | Upgrade | Citigroup | Sell → Neutral |
| Dec-09-20 | Initiated | Oppenheimer | Perform |
| Nov-17-20 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Oct-08-20 | Downgrade | JP Morgan | Neutral → Underweight |
| Jun-15-20 | Initiated | Jefferies | Hold |
| Mar-05-20 | Initiated | Citigroup | Sell |
| Feb-28-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-06-20 | Upgrade | Berenberg | Hold → Buy |
| Dec-12-19 | Downgrade | Wells Fargo | Outperform → Underperform |
| Sep-30-19 | Downgrade | BofA/Merrill | Buy → Underperform |
| Mar-08-19 | Initiated | BTIG Research | Neutral |
| Aug-30-18 | Initiated | Berenberg | Hold |
| Aug-29-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-03-18 | Reiterated | Stifel | Hold |
| Jun-21-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-13-18 | Downgrade | Stifel | Buy → Hold |
| Mar-01-18 | Reiterated | Cantor Fitzgerald | Buy |
| Mar-02-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-06-17 | Upgrade | Stifel | Hold → Buy |
| Oct-27-16 | Initiated | Wells Fargo | Outperform |
View All
Glaukos Corp Stock (GKOS) Latest News
Glaukos Market Cap More Than Doubles in a Year to $11B - Orange County Business Journal
Glaukos Corporation (NYSE:GKOS) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Oppenheimer Asset Management Inc. Invests $2.73 Million in Glaukos Corporation $GKOS - MarketBeat
3 Stocks That May Be Trading Below Their Estimated Value By Up To 50% - Sahm
Walleye Capital LLC Takes $3.75 Million Position in Glaukos Corporation $GKOS - MarketBeat
Glaukos Insider Sold Shares Worth $10,784,659, According to a Recent SEC Filing - marketscreener.com
Glaukos COO Joseph Gilliam sells $10.7m in stock By Investing.com - Investing.com Nigeria
Insider Selling: Glaukos (NYSE:GKOS) COO Sells 60,000 Shares of Stock - MarketBeat
Glaukos COO Joseph Gilliam sells $10.7m in stock - Investing.com
Glaukos(GKOS.US) Officer Sells US$10.78 Million in Common Stock - Moomoo
Glaukos Corporation (GKOS) Stock Forecasts - Yahoo! Finance Canada
Glaukos (NYSE:GKOS) Hits New 12-Month HighHere's What Happened - MarketBeat
Glaukos Corp stock hits all-time high at 184.45 USD - Investing.com
Glaukos SVP & CFO Alex Thurman sells $3.6m in GKOS stock - Investing.com
Insider Selling: Glaukos (NYSE:GKOS) CFO Sells 20,000 Shares of Stock - MarketBeat
Glaukos Insider Sold Shares Worth $3,602,600, According to a Recent SEC Filing - marketscreener.com
GLAUKOS Corp SEC Filing (Aug 11, 2026) - Stock Titan
Assenagon Asset Management S.A. Has $15.20 Million Stock Position in Glaukos Corporation $GKOS - marketbeat.com
Why Is Glaukos (NYSE:GKOS) Surging Toward the Top of Smallcap Medtech? - Kalkine Media
Glaukos Corporation $GKOS Shares Acquired by Bank of America Corp DE - MarketBeat
Quantinno Capital Management LP Raises Position in Glaukos Corporation $GKOS - MarketBeat
A Look at Glaukos Corp (GKOS) After 5.3% Gain -- GF Value $147.7 - GuruFocus
Glaukos (GKOS) Q2 2026 Earnings Call Transcript - theglobeandmail.com
Glaukos (NYSE: GKOS) insider Alex R. Thurman plans 20,000-share stock sale - Stock Titan
Glaukos Corp (GKOS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Dimensional Fund Advisors LP Sells 6,377 Shares of Glaukos Corporation $GKOS - MarketBeat
Royal Bank of Canada Purchases 12,253 Shares of Glaukos Corporation $GKOS - MarketBeat
California State Teachers Retirement System Purchases 11,871 Shares of Glaukos Corporation $GKOS - MarketBeat
First Trust Advisors LP Acquires 40,798 Shares of Glaukos Corporation $GKOS - MarketBeat
Glaukos posts investor presentation outlining iDose TR, Epioxa launch and pipeline depth - TradingView
Renaissance Technologies LLC Purchases New Shares in Glaukos Corporation $GKOS - MarketBeat
Glaukos (NYSE:GKOS) Raised to "Buy" at Wall Street Zen - MarketBeat
H.C. Wainwright raises Glaukos stock price target on strong results - Investing.com Nigeria
Glaukos Reports Record Q2 Sales, Raises 2026 Outlook - VisionMonday.com
GKOS Maintained by Stifel -- Price Target Raised to $190 - GuruFocus
Glaukos Q2 Earnings Beat Estimates on iDose TR Growth, Stock Up - Zacks Investment Research
Stifel raises Glaukos stock price target to $190 on revenue outlook - Investing.com Nigeria
UBS Adjusts Price Target on Glaukos Corp to $172 From $150, Maintains Neutral Rating - marketscreener.com
GKOS Maintained by Needham -- Price Target Raised to $201 - GuruFocus
Needham raises Glaukos stock price target to $201 on guidance boost - Investing.com Nigeria
Truist raises Glaukos stock price target to $215 on higher estimates - Investing.com Nigeria
Glaukos (NYSE:GKOS) Reaches New 1-Year High on Strong Earnings - MarketBeat
Glaukos Corp reports results for the quarter ended June 30Earnings Summary - TradingView
Glaukos: Q2 Earnings Snapshot - KTVB
Glaukos Corporation (GKOS) Stock Rises on Q2 2026 Earnings - Quiver Quantitative
Glaukos Corp stock hits 52-week high at 161.67 USD By Investing.com - Investing.com Nigeria
Glaukos Rises as Investors Weigh Clinical Progress Ahead of Earnings - Quiver Quantitative
Glaukos (NYSE:GKOS) Posts Quarterly Earnings Results, Beats Expectations By $0.07 EPS - MarketBeat
Stifel reiterates Glaukos stock rating on Epioxa demand strength By Investing.com - Investing.com Canada
UBS Group Begins Coverage on Glaukos (NYSE:GKOS) - MarketBeat
Glaukos Announces Completion of Patient Enrollment in 510(k) Pivotal Study for PRESERFLO™ MicroShunt - BioSpace
Glaukos Corp Stock (GKOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):